Related to Merck Dampens 2013 Expectations After Q4 Profits Slide

• The Status of U.S. and European Government Funding for Synthetic Biology
  
• Merck Teams with Adcock Ingram to Market OTC and Rx Products in South Africa
  
• CHMP Doles Out Two Positive Opinions on Archimedes Pharma and Merck & Co. Drugs
  
• Diabetes Therapy Company Poxel Raises $21M in Series A Financing
  
• Merck & Co. to Axe 16 Research and Manufacturing Facilities as Post-Merger Restructuring Heats Up
  
• Pfizer to Study Liver Cancer in Korean Patients with Samsung Medical Center
  
• Cara Raises $15M in Series D Fundraising for Phase II Development of Pain Relief Drug
  
• Cerenis Raises €40M in Series C and Wins €10.7M from French Government
  
• LabCorp Gains Rights to Merck & Co.’s IL-28B Polymorphism IP for HCV Therapy Predictive Test
  
• EU Sanctions Merck & Co.'s Sublingual Bipolar Disorder Drug Sycrest
  
• Merck & Co. and BGI Intend to Work Together to Advance Genomics in Medicine
  
• Belgian Tech-Transfer Organization Gets Additional €16M from K.U. Leuven and EIF
  
• Merck & Co. Returns Rights to Mid-Stage Anticancer Agent to AVEO
  
• Merck Ditches Phase III Study Evaluating Once-Daily Dosing of HIV Drug Isentress
  
• Merck & Co. to Take Over SmartCells for Platform that Auto-Regulates Drug Release
  
• Merck & Co., MVI, and NYU Langone Medical Center Partner to Develop Malaria Vaccine
  
• FDA Expands Gardasil Label to Include Anal Cancer
  
• Merck BioVentures Taps Parexel to Help Develop a Range of Biosimilars
  
• Merck & Co. Axes Partnership with Galapagos
  
• Merck and Lycera to Develop Oral Autoimmune Disease Drugs Targeting Th17 Cells